SCHEMBL5125902

SCHEMBL5125902

CCc1cccc(CN(C[C@@H](O)[C@@H](N)Cc2cc(F)cc(F)c2)C(=O)CCCC(=O)Nc2cccc(C(C)=O)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
PARP1 P09874 1/20 0.39
PARP10 Q53GL7 1/20 0.39
CTSD P07339 2/20 0.38
BACE1 P56817 2/20 0.38
ALDH1A1 P00352 3/20 0.37
LMNA P02545 3/20 0.37
MAPT P10636 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5579835 0.94 PPARA (0.38) KMT2AMEN1HDAC3HDAC4HDAC1
SCHEMBL5131035 0.88 LMNA (0.41) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5130327 0.85 BACE1 (0.40) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5116565 0.85 BACE1 (0.38) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5131129 0.85 POLB (0.41) KMT2AMEN1HDAC3HDAC1CTSD
SCHEMBL5126595 0.83 LMNA (0.41) KMT2AMEN1CTSDBACE1LMNA
SCHEMBL5120535 0.82 EPHX2 (0.41) KMT2AMEN1HDAC3HDAC4HDAC1
SCHEMBL5120921 0.82 HTT (0.42) KMT2AMEN1CTSDBACE1ALDH1A1
SCHEMBL5129943 0.82 BACE1 (0.43) HDAC3CTSDBACE1NPC1RAB9A
SCHEMBL5120761 0.80 ALDH1A1 (0.40) KMT2AMEN1CTSDBACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 KMT2A 2573/4885MEN1 1613/4885HDAC3 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.